Intelligence · Clinical Development
Pipeline search results
Programs matching “multiple-myeloma” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 167 pipeline programs matching "multiple-myeloma" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Elotuzumab
Atrium Therapeutics
Multiple Myeloma
1 trial -
Etoposide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
GEN3014
Genmab A/S
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
GPC-100
Structure Therapeutics
Multiple Myeloma
1 trial -
IL-15-armored CAR-T cells
The First People's Hospital of Lianyungang
Relapsed/Refractory Multiple Myeloma
1 trial -
IST-342
Karyopharm Therapeutics Inc
Relapsed Multiple Myeloma
1 trial -
Isatuximab
Sanofi Pasteur
Relapsed/Refractory Multiple Myeloma
1 trial -
Ixazomib
Takeda
Multiple Myeloma
15 trials -
Ixazomib
Takeda
Smoldering Multiple Myeloma
1 trial -
Ixazomib
Takeda
Relapsed/Refractory Multiple Myeloma
1 trial -
Ixazomib
Takeda
Newly Diagnosed Multiple Myeloma
1 trial -
Ixazomib/Pomalidomide/Dexamethasone
Takeda
Multiple Myeloma
1 trial -
KPT-8602
Karyopharm Therapeutics Inc
Relapsed/Refractory Multiple Myeloma (RRMM)
1 trial -
KW-2478
KYOWA KIRIN AUSTRALIA PTY LTD
Multiple Myeloma
1 trial -
LCAR-B38M CAR-T Cell
Nanjing Legend Biotech Co.
Multiple Myeloma
1 trial -
LCAR-B38M CAR-T cell injection
Nanjing Legend Biotech Co.
Refractory or Relapsed Multiple Myeloma
1 trial -
Linvoseltamab
Regeneron UK Limited
Smoldering Multiple Myeloma (SMM)
1 trial -
Linvoseltamab
Regeneron UK Limited
Relapsed/Refractory Multiple Myeloma
1 trial -
Linvoseltamab
Regeneron UK Limited
Recurrent Multiple Myeloma
1 trial -
Melphalan
Takeda
Multiple Myeloma
1 trial -
Melphalan flufenamide (Melflufen)
Chongqing Precision Biotech Co., Ltd
Multiple Myeloma
1 trial -
Modakafusp alfa
Teva Pharma GmbH
Multiple Myeloma
3 trials -
MyDRUG (MMRC-085)
Karyopharm Therapeutics Inc
Relapsed Refractory Multiple Myeloma
1 trial -
Nivolumab
Takeda
Relapsed Multiple Myeloma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.